Skip to main content
SpringerLink
Log in

Economic evaluation of ezetimibe combined with simvastatin for the treatment of primary hypercholesterolaemia

  • Original Article
  • Published:
Netherlands Heart Journal Aims and scope Submit manuscript

Abstract

Objective

This study aims to assess the cost-effectiveness of ezetimibe plus simvastatin (E/S) versus atorvastatin or simvastatin monotherapy as second-line treatment of primary hypercholesterolaemia from the Dutch healthcare perspective.

Methods

The evaluation used a Markov model and patient data from the Dutch EASEGO study in which patients failing to reach goal low-density lipoprotein cholesterol levels on atorvastatin 10 mg or simvastatin 20 mg had their dose doubled or switched to ezetimibe 10 mg plus generic simvastatin 20 mg (E10/S20). The second scenario, based on Dutch guidelines, switched patients from simvastatin 40 mg to atorvastatin 40 mg, or ezetimibe 10 mg was added to simvastatin 40 mg (E10/S40). The key effectiveness input measure was change in total cholesterol/high-density lipoprotein ratio obtained from the EASEGO study. In conformity with published studies linking reduced lipid levels to reduced risk of cardiovascular events, the present model assumed that a lipid decrease with ezetimibe may be a signal for reduced risk of cardiovascular events. Model parameters were derived from published literature. Sensitivity analyses were performed for the key parameters.

Results

In the EASEGO scenario, incremental cost-effectiveness ratio for E10/S20 was €3497/quality-adjusted life-years (QALY) vs atorvastatin 20 mg and €26,417/QALY vs simvastatin 40 mg. In the Dutch guidelines scenario, E10/S40 was dominant (more effective and cost-saving) vs atorvastatin 40 mg. Varying model inputs had limited impact on the cost-effectiveness of E/S.

Conclusions

The analysis showed the cost-effectiveness of E/S versus atorvastatin 20 mg or simvastatin 40 mg (EASEGO scenario) at a threshold of €30,000/QALY and vs atorvastatin 40 mg was dominant (Dutch guidelines). Thus, E/S seems a valuable cost-effective second-line treatment option for patients not attaining lipid treatment goals.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Allender S, Scarborough P, Peto V. European Cardiovascular Statistics. Oxford: European Health Network; 2008.

    Google Scholar 

  2. Molina JA, Heng BH. Global trends in cardiology and cardiothoracic surgery—an opportunity or a threat? Ann Acad Med Singapore. 2009;38(6):541–5.

    PubMed  Google Scholar 

  3. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003;326(7404):1423.

    Article  PubMed  CAS  Google Scholar 

  4. Dembowski E, Davidson MH. Statin and ezetimibe combination therapy in cardiovascular disease. Curr Opin Endocrinol Diab Obes. 2009;16(2):183–8.

    Article  CAS  Google Scholar 

  5. Kastelein JJ, de Groot E. Ultrasound imaging techniques for the evaluation of cardiovascular therapies. Eur Heart J. 2008;29(7):849–58.

    Article  PubMed  Google Scholar 

  6. Goldberg AC, Sapre A, Liu J, et al. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc. 2004;79(5):620–9.

    Article  PubMed  CAS  Google Scholar 

  7. Montecucco F, Quercioli A, Mach F. Ezetimibe/simvastatin. Expert Opin Drug Saf. 2009;8(6):715–25.

    Article  PubMed  CAS  Google Scholar 

  8. Bays H, Sapre A, Taggart W, et al. Long-term (48-week) safety of ezetimibe 10 mg/day coadministered with simvastatin compared to simvastatin alone in patients with primary hypercholesterolemia. Curr Med Res Opin. 2008;24(10):2953–66.

    Article  PubMed  CAS  Google Scholar 

  9. Brudi P, Reckless JP, Henry DP, et al. Efficacy of ezetimibe/simvastatin 10/40 mg compared to doubling the dose of low-, medium- and high-potency statin monotherapy in patients with a recent coronary event. Cardiology. 2009;113(2):89–97.

    Article  PubMed  CAS  Google Scholar 

  10. Perkerson KA, Gillespie EL, Coleman CI. Cost-effectiveness of statin monotherapy and combination therapy with ezetimibe. Conn Med. 2005;69(1):19–22.

    PubMed  Google Scholar 

  11. Roeters van Lennep HW, Liem AH, Dunselman PH, et al. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study. Curr Med Res Opin. 2008;24(3):685–94.

    Article  PubMed  CAS  Google Scholar 

  12. Reckless JP, Henry P, Pomykaj T, et al. Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study. Int J Clin Pract. 2008;62(4):539–54.

    Article  PubMed  CAS  Google Scholar 

  13. Farnier M, Averna M, Missault L, et al. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy—the IN-CROSS study. Int J Clin Pract. 2009;63(4):547–59.

    Article  PubMed  CAS  Google Scholar 

  14. Fleg JL, Mete M, Howard BV, et al. Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. J Am Coll Cardiol. 2008;52(25):2198–205.

    Article  PubMed  CAS  Google Scholar 

  15. Rossebo AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359(13):1343–56.

    Article  PubMed  Google Scholar 

  16. Cook JR, Yin D, Alemao E, et al. Cost-effectiveness of ezetimibe coadministration in statin-treated patients not at cholesterol goal: application to Germany, Spain and Norway. Pharmacoeconomics. 2004;22 Suppl 3:49–61.

    PubMed  Google Scholar 

  17. Cook JR, Yin D, Alemao E, et al. Development and validation of a model to project the long-term benefit and cost of alternative lipid-lowering strategies in patients with hypercholesterolaemia. Pharmacoeconomics. 2004;22 Suppl 3:37–48.

    PubMed  Google Scholar 

  18. Kohli M, Attard C, Lam A, et al. Cost effectiveness of adding ezetimibe to atorvastatin therapy in patients not at cholesterol treatment goal in Canada. Pharmacoeconomics. 2006;24(8):815–30.

    Article  PubMed  Google Scholar 

  19. National Institute for Health and Clinical Excellence. Ezetimibe for the Treatment of Primary (heterozygous-familial and non-familial) hypercholesterolaemia. NICE Technology Appraisal Guidance 132. [http://www.nice.org.uk/nicemedia/live/11886/38213/38213.doc] Accessed on 18 Jun 2010

  20. Ara R, Pandor A, Tumur I, et al. Estimating the health benefits and costs associated with ezetimibe coadministered with statin therapy compared with higher dose statin monotherapy in patients with established cardiovascular disease: results of a Markov model for UK costs using data registries. Clin Ther. 2008;30(8):1508–23.

    Article  PubMed  Google Scholar 

  21. Soini EJ, Davies G, Martikainen JA, et al. Population-based health-economic evaluation of the secondary prevention of coronary heart disease in Finland. Curr Med Res Opin. 2010;26(1):25–36.

    Article  PubMed  Google Scholar 

  22. Westert GP, van den Berg MJ, Koolman X, et al. Dutch Health Care Performance Report. Bilthoven, the Netherlands: National Institute for Public Health and the Environment. [http://www.rivm.nl/vtv/object_binary/o6118_Dutch%20Healthcare%20Performance%20Report%202008.pdf] Accessed 11 Jun 2010

  23. Dutch Ministry of Foreign Affairs: Welcome to the Netherlands: Health Care. 2009.

  24. D’Agostino RB, Russell MW, Huse DM, et al. Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J. 2000;139(2 Pt 1):272–81.

    PubMed  Google Scholar 

  25. D’Agostino Sr RB, Grundy S, Sullivan LM, et al. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA. 2001;286(2):180–7.

    Article  PubMed  Google Scholar 

  26. Oostenbrink J. Handleiding voor kostenonderzoek. Methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg. CVZ 2005.

  27. Greving JP, Buskens E, Koffijberg H, et al. Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk. Circulation. 2008;117(22):2875–83.

    Article  PubMed  Google Scholar 

  28. van Hout BA, Simoons ML. Cost-effectiveness of HMG coenzyme reductase inhibitors; whom to treat? Eur Heart J. 2001;22(9):751–61.

    Article  PubMed  Google Scholar 

  29. Goodacre S, Nicholl J, Dixon S, et al. Randomised controlled trial and economic evaluation of a chest pain observation unit compared with routine care. BMJ. 2004;328(7434):254.

    Article  PubMed  Google Scholar 

  30. College van Zorgverzekeraars: Handboek voor kostenonderzoek 2004 van het College van Zorgverzekeraars. 2009.

  31. Nederlands Zorgautoriteit: Tarieflijst zorginstellingen 2009 from the Nederlands Zorgautoriteit. 2009.

  32. Z-index, taxe February 2009.

  33. Busschbach J, Rabin R, De Charro F, Proceedings of the 24th Scientific Plenary Meeting of the EuroQol Group. Kijkduin. In EuroQoL: The Hague, the Netherlands; 2007.

  34. Lamers LM, Stalmeier PF, McDonnell J, et al. Measuring the quality of life in economic evaluations: the Dutch EQ-5D tariff. Ned Tijdschr Geneeskd. 2005;149(28):1574–8.

    PubMed  CAS  Google Scholar 

  35. Califf RM, Lokhnygina Y, Cannon CP, et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design. Am Heart J. 2010;159(5):705–9.

    Article  PubMed  Google Scholar 

Download references

Acknowledgement

This work was funded by Merck Sharpe and Dohme/Schering-Plough Pharmaceuticals, the Netherlands. The authors wish to thank Steven Siak of United BioSource Corporation for assistance in the preparation of the manuscript and Carla Vos and Judith Breteler of Merck Sharp & Dohme Corporation for their valuable comments on the manuscript.

Author information

Authors and Affiliations

  1. United BioSource Corporation, 26-28 Hammersmith Grove, London, W6 7HA, UK

    F. van Nooten

  2. Merck Research Laboratories, Upper Gwynedd, PA, USA

    G. M. Davies

  3. Leiden University Medical Center, Department of Cardiology, Leiden, the Netherlands

    J. W. Jukema

  4. Admiraal de Ruyter Ziekenhuis, Department of Cardiology, Goes, the Netherlands

    A. H. Liem

  5. Schering-Plough, Houten, the Netherlands

    E. Yap

  6. Merck & Co., Inc, West Point, PA, USA

    X. H. Hu

Authors
  1. F. van Nooten
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. M. Davies
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. W. Jukema
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. H. Liem
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E. Yap
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. X. H. Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to F. van Nooten.

Additional information

The questions can be answered after the article has been published in print. You have to log in to: www.cvoi.nl.

Rights and permissions

Reprints and permissions

About this article

Cite this article

van Nooten, F., Davies, G.M., Jukema, J.W. et al. Economic evaluation of ezetimibe combined with simvastatin for the treatment of primary hypercholesterolaemia. Neth Heart J 19, 61–67 (2011). https://doi.org/10.1007/s12471-010-0061-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12471-010-0061-5

Keywords

Search

Navigation